A Medical Device Daily

ResMed (San Diego) reported that its board of directors has unanimously approved a succession plan for executive management of the company.

Effective Jan. 1, 2008, Kieran Gallahue will be promoted to CEO and will join the board of directors. Gallahue, 44, will succeed Dr. Peter Farrell, 65. As of Jan. 1, 2008, Farrell will relinquish his position as CEO, but will continue serving as executive chairman of the board until June 30, 2008, when he will become non-executive chairman.

“Since joining ResMed in 2003, Kieran has demonstrated strong leadership qualities,” said Farrell. “He has been instrumental in improving our operational execution, targeting our research and development efforts, focusing our commercial teams to better serve patients and customers, while strengthening the depth of our management. As Chairman, I intend to remain significantly engaged in the company’s mission and strategy.”

Gallahue joined ResMed in January 2003 as president and COO of the Americas. He was named president and COO, ResMed Global, in September 2004.

Prior to joining ResMed, Gallahue served as president of Nanogen (San Diego), a DNA research and medical diagnostics company.

ResMed is a manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders.